SVRA News and Press, Savara Inc. From 03/06/23

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live webcast of the presentation will be avai...

Summary Savara has mapped out a simple destiny in pursuit of approval for its lead therapy. Recent interest in and support of Savara is overblown. Single minded focus on its lead therapy allows Savara to limit capital outlays. This is my first take on Savara Inc. ( SVRA ),...

Rob Lutz Appointed Chief Operating Officer Scott Wilhoit Appointed Executive Vice President, Global Commercial Dave Lowrance, Promoted to Chief Financial and Administrative Officer Company Focused on Completing Enrollment for IMPALA-2, the Phase 3 Pivotal Trial of Molgramo...

Shares of Savara (NASDAQ: SVRA) , a clinical-stage biopharmaceutical company that specializes in rare respiratory diseases, were up 31.6% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence . The stock closed last week at $2.09, then h...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award. On November 21, 2022, Savara's Board of Directors granted the inducement award to Raymond Pratt, M.D., who join...

Pivotal Phase 3 IMPALA-2 Trial Remains On-Track, Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease ...

Jefferies London Healthcare Conference Piper Sandler 34th Annual Healthcare Conference Evercore ISI 5th Annual HealthCONx Conference Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announc...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6 th in Barcelona, Spain. Below are summaries of each poster presented: ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright 24 th Annual Global Investment Conference being held September 12-14, 2022. A w...

Savara ( NASDAQ: SVRA ) Badrul Chowdhury resigned as chief medical officer, effective Sept. 9. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future," ...